DCF Advisers’s AstraZeneca AZN Stock Holding History

DCF Advisers’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$901K	Sell	4,750 -1,000	-17%	-$188K	0.16%	66
2026 Q1	$1.13M	Sell	5,750 -16,400	-74%	-$3.16M	0.3%	56
2025 Q4	$4.07M	Buy	+22,150	New	+$3.88M	1.09%	28
2025 Q3	–	Sell	-22,900	Closed	-$3.2M	–	98
2025 Q2	$3.2M	Hold	22,900	–	–	1.48%	23
2025 Q1	$3.37M	Buy	+22,900	New	+$3.31M	1.61%	21
2022 Q1	–	Sell	-6,373	Closed	-$742K	–	71
2021 Q4	$742K	Hold	6,373	–	–	0.3%	52
2021 Q3	$765K	Buy	+6,373	New	+$742K	0.34%	53

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

DCF Advisers's AZN Position: Q2 2026 in Review

DCF Advisers reduced its AstraZeneca (AZN) stake by 17% in Q2 2026, selling an estimated $188K and leaving 4,750 shares worth $901K. The position accounts for 0.16% of the portfolio, ranked #66.

DCF Advisers first reported a position in AZN in Q3 2021 and has held it in 7 quarters since. The position peaked at $4.07M in Q4 2025. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

DCF Advisers held 4,750 shares of AstraZeneca worth $901K as of Q2 2026.
DCF Advisers sold 1,000 AstraZeneca shares in Q2 2026, an estimated $188K.
AstraZeneca made up 0.16% of DCF Advisers's portfolio in Q2 2026, its #66 holding.
DCF Advisers first reported a position in AstraZeneca in Q3 2021 and has held it in 7 quarters since.
DCF Advisers's AstraZeneca position peaked at $4.07M in Q4 2025.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.